Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback